Treatment Resistant Schizophrenia

Approximately 30% of people with schizophrenia have treatment-resistant schizophrenia (TRS), meaning they have not responded to at least two antipsychotic trials.

Research into TRS is ongoing, with developments in assessment and treatment helping to improve the functional outcomes and quality of life of individuals and their carers.

This self-guided online course brings together the latest research and developments in clinical practice to provide health professionals with a comprehensive understanding and up-to-date summary of the epidemiology, assessment and treatment of TRS. For those with an understanding of TRS, it provides a refresher in these key areas.

Developed by experts from the Department of Psychiatry, the course is equivalent to one hour of continuing professional development, subject to peer group approval.

Gain deeper knowledge of treatment-resistant schizophrenia

Advance your understanding of treatment-resistant schizophrenia by exploring its epidemiology. Use this knowledge to better understand the evaluation of TRS as well as medication and management.

Examine the role of clozapine in treatment

Explore the role of clozapine and monitoring requirements, as well as clozapine resistance and augmentation.

Gain practical tools to apply to your practice

From the evaluation of TRS through to medication and management, you'll gain practical knowledge and skills which you can apply immediately. Content also includes several practical tools, such as guidelines for assessment, which will be useful for your own practice.